Home > Insider Trading > Filing (0001181431-10-055859)

Filing Details

Accession Number:: 0001181431-10-055859
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-11-16 14:05:16
Reporting Period:: 2010-11-16

Filing Date:: 2010-11-16
Accepted Time:: 2010-11-16 14:05:16
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1361103	Complete Genomics Inc	GNOM	Services-Commercial Physical & Biological Research (8731)	203226545

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1055951	Orbimed Advisors Llc	767 Third Avenue, 30Th Floor New York NY 10017		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.001	Acquisiton	2010-11-16	2,252,898	$0.00	2,252,898	No	4	C	Indirect	See Footnotes
Common Stock, Par Value $0.001	Acquisiton	2010-11-16	1,267,070	$0.00	3,519,968	No	4	C	Indirect	See Footnotes
Common Stock, Par Value $0.001	Acquisiton	2010-11-16	597,091	$9.00	4,117,059	No	4	P	Indirect	See Footnotes
Common Stock, Par Value $0.001	Acquisiton	2010-11-16	21,456	$0.00	21,456	No	4	C	Indirect	See Footnotes
Common Stock, Par Value $0.001	Acquisiton	2010-11-16	12,068	$0.00	33,524	No	4	C	Indirect	See Footnotes
Common Stock, Par Value $0.001	Acquisiton	2010-11-16	5,687	$9.00	39,211	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series D Preferred Stock	Disposition	2010-11-16	2,252,898	$0.00	2,252,898	$0.00
Common Stock	Series D Preferred Stock	Disposition	2010-11-16	21,456	$0.00	21,456	$0.00
Common Stock	Series E Preferred Stock	Disposition	2010-11-16	1,267,070	$0.00	1,267,070	$0.00
Common Stock	Series E Preferred Stock	Disposition	2010-11-16	12,068	$0.00	12,068	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of Series D and Series E Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering.
The shares of Preferred Stock and shares of Common Stock (together "Shares")reported herein as indirectly beneficially owned by OrbiMed Capital GP III LLC ("Capital"), OrbiMed Advisors LLC ("Advisors") and Samuel D. Isaly ("Isaly") are directly owned by OrbiMed Private Investments III, LP (formerly, Caduceus Private Investments III, LP) ("OPI III") and OrbiMed Associates III, LP ("Associates"). Each of Capital, Advisors and Isaly may be deemed to have a pecuniary interest in Shares beneficially owned by OPI III and each of Advisors and Isaly may be deemed to have a pecuniary interest in Shares beneficially owned by Associates. This Form 4 is being jointly filed by Capital, Advisors and Isaly. The Reporting Persons have designated a representative, currently Carl L. Gordon, a member of Advisors, to serve on the Issuer's board of directors.
These Shares are beneficially owned by OPI III. Capital is the sole general partner of OPI III. Advisors, a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of Capital. Advisors and Capital may be deemed to have beneficial ownership of Shares held by OPI III by virtue of such relationships. Isaly, a natural person, may be deemed to have beneficial ownership of such Shares in his capacity as the managing member of, and holder of a controlling interest, in Advisors.
These Shares are beneficially owned by Associates. Advisors is the sole general partner of Associates and may be deemed to have beneficial ownership of Shares held by Associates by virtue of that relationship. Isaly, a natural person, may be deemed to have beneficial ownership of such Shares in his capacity as the managing member of, and holder of a controlling interest, in Advisors.
Each of Advisors, Capital and Isaly disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Persons are beneficial owners for the purpose of Section 16 of the Exchange Act, or for any other purpose.
The securities are immediately convertible.
The expiration date is not relevant to the conversion of these securities.
OPI III purchased an additional 597,091 shares of Common Stock and Associates purchased an additional 5,687 shares of Common Stock in connection with the initial public offering at the offering price of $9.00 per share.